title: 111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
abstract: Somatostatin receptor (SSTR) scintigraphy and gallium-67 citrate ((67)Ga) scintigraphy have been used for visualisation of Hodgkin's lymphoma and non-Hodgkin's lymphoma. However, experience with B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type is very limited. The aim of this study was to prospectively compare the (67)Ga scintigraphy results with those obtained by (111)In-DOTA- dPhe(1)-Tyr(3)-octreotide ((111)In-DOTA-TOCT) and (111)In-DOTA-lanreotide ((111)In-DOTA-LAN) scintigraphy in patients with proven MALT-type lymphoma. Comparative scintigraphic examinations using (67)Ga, (111)In-DOTA-TOCT and (111)In-DOTA-LAN were performed in 18 patients (11 female and 7 male, median age 64+/-15 years) with histologically verified MALT-type lymphomas of various origin. Planar and single-photon emission tomography imaging acquisitions were performed after injection of a mean dose of 185+/-26 MBq (67)Ga and 165+/-20 MBq (111)In-DOTA-TOCT or (111)In-DOTA-LAN. All scintigraphic results were correlated with other conventional examinations including gastroscopy, colonoscopy, endosonoscopy, ophthalmologic investigation, CT of the thorax and abdomen and bone marrow biopsy. This comparative study showed that (67)Ga scintigraphy found abnormalities in 10 of 16 patients (63%) and detected 18 of 31 clinically involved sites (58%), but was false positive in three patients. (111)In-DOTA-TOCT found abnormalities in 9 of 15 patients (60%) and detected 15 of 27 clinical lesions (56%); it was false positive in two patients. (111)In-DOTA-LAN scintigraphy showed abnormalities in 7 of 11 patients (64%) and found 12 of 22 clinical lesions (55%). False-positive (111)In-DOTA-LAN scan results were found in two patients. For supra-diaphragmatic lesions, (67)Ga scintigraphy detected 12 of 16 sites (75%). (111)In-DOTA-TOCT scintigraphy revealed 7 of 15 lesions (47%). (111)In-DOTA-LAN showed 6 of 12 positive sites (50%). For infra-diaphragmatic involvement, the sensitivities of (67)Ga, (111)In-DOTA-TOCT and (111)In-DOTA-LAN were 40%, 67% and 60%, respectively. It is concluded that MALT-type lymphoma can be visualised by (67)Ga, (111)In-DOTA-TOCT and (111)In-DOTA-LAN scintigraphy. Although there were no statistically significant differences in patient-related and site-related sensitivities when using (67)Ga compared with (111)In-DOTA-TOCT and (111)In-DOTA-LAN, the sensitivity of (67)Ga tended to be superior to that of (111)In-DOTA-TOCT and (111)In-DOTA-LAN for supra-diaphragmatic lesions but inferior for infra-diaphragmatic involvement. In selected cases, the combination of (67)Ga and (111)In-DOTA-LAN or (111)In-DOTA-TOCT may increase the diagnostic efficiency in patients with MALT-type lymphoma.
authors.affiliation: Department of Nuclear Medicine, University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria, shuren.li@akh-wien.ac.at
authors.forename: Shuren
authors.initials: S
authors.lastname: Li
authors.forename: Amir
authors.initials: A
authors.lastname: Kurtaran
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.forename: Tatjana
authors.initials: T
authors.lastname: Traub-Weidinger
authors.forename: Oskar
authors.initials: O
authors.lastname: Kienast
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schima
authors.forename: Peter
authors.initials: P
authors.lastname: Angelberger
authors.forename: Irene
authors.initials: I
authors.lastname: Virgolini
authors.forename: Markus
authors.initials: M
authors.lastname: Raderer
authors.forename: Robert
authors.initials: R
authors.lastname: Dudczak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002951:Citrates; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D005708:Gallium; D006571:Heterocyclic Compounds; D006801:Humans; D007205:Indium Radioisotopes; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives*; D010456:Peptides, Cyclic; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D002951:Citrates; D006571:Heterocyclic Compounds; D007205:Indium Radioisotopes; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; C116409:indium 111-DOTA-lanreotide; D005708:Gallium; C103850:gallium citrate; D015282:Octreotide; C106246:Edotreotide